Clinical translation of angiogenesis inhibitors (original) (raw)

• Folkman, J. in Harrison's Textbook of Internal Medicine 15th edn (eds Braunwald, E. et al.) 517–530 (McGraw–Hill, New York, 2001).
  Google Scholar
• Hanahan, D. & Weinberg, R. The hallmarks of cancer. Cell 100, 57–70 (2000).
  CAS PubMed Google Scholar
• Hanahan, D. & Folkman, J. Parameters and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–364 (1996.)Experimental evidence for the angiogenic switch.
  CAS PubMed Google Scholar
• Rak, J., Yu, J. L., Klement, G. & Kerbel, R. S. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J. Invest. Dermatol. Symp. Proc. 5, 24–33 (2000).This review summarizes the ability of almost 20 known oncogenes to regulate inducers or inhibitors of angiogenesis, and highlights the link between oncogenes and tumour angiogenesis.
  CAS Google Scholar
• Relf, M. et al. Expression of the angiogenic factors vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumour growth factor-β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57, 963–969 (1997).
  CAS PubMed Google Scholar
• Carmeliet, P. et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485–490 (1998).
  CAS PubMed Google Scholar
• Fukumura, D. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715–725 (1998).
  CAS PubMed Google Scholar
• Shi, Q. et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 92, 362–367 (1998).
  CAS PubMed Google Scholar
• Dameron, K. M., Volpert, O. V., Tainsky, M. A. & Bouck, N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582–1584 (1994).
  CAS PubMed Google Scholar
• Kerbel, R. S. Inhibition of tumour angiogenesis as a strategy to circumvent acquired resistance to anticancer therapeutic agents. Bioessays 13, 31–36 (1991).This commentary advanced the hypothesis that anti-angiogenic therapy might bypass acquired drug resistance by targeting the genetically stable, host endothelial cells of tumour vessels. It also raised the prospect of conventional chemotherapeutic drugs having antitumour properties, even against drug-resistant tumours, by targeting the dividing endothelial cells of tumour vessels — a theory which eventually led to the development of low-dose 'metronomic'/anti-angiogenic chemotherapy.
  CAS PubMed Google Scholar
• Boehm, T., Folkman, J., Browder, T. & O'Reilly, M. S. Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404–407 (1997).
  CAS PubMed Google Scholar
• Kerbel, R. S., Viloria-Petit, A., Okada, F. & Rak, J. Establishing a link between oncogenes and tumor angiogenesis. Mol. Med. 4, 286–295 (1998).
  CAS PubMed PubMed Central Google Scholar
• Rak, J., Yu, J. L., Kerbel, R. S. & Coomber, B. L. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res. 62, 1931–1934 (2002).
  CAS PubMed Google Scholar
• Viloria-Petit, A. et al. Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumour cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumours. Am. J. Pathol. 151, 1523–1530 (1997).
  Google Scholar
• Fernandez, A. et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J. Natl Cancer Inst. 93, 33–38 (2001).
  Google Scholar
• Arbiser, J. L. et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl Acad. Sci. USA 94, 861–866 (1997).
  CAS PubMed PubMed Central Google Scholar
• Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468–472 (1999).
  CAS PubMed Google Scholar
• Udagawa, T., Fernandez, A., Achilles, E. G., Folkman, J. & D'Amato, R. J. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J. 16, 1361–1370 (2002).
  CAS PubMed Google Scholar
• Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor-1α. Genes Dev. 14, 34–44 (2000).
  CAS PubMed PubMed Central Google Scholar
• Zhang, L. et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 60, 3655–3661 (2000).
  CAS PubMed Google Scholar
• Sherif, Z. A., Nakai, S., Pirollo, K. F., Rait, A. & Chang, E. H. Down-modulation of bFGF-binding protein expression following restoration of p53 function. Cancer Gene Ther. 8, 771–782 (2001).
  CAS PubMed Google Scholar
• Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D. & Jain, R. K. Tumor biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416, 279–280 (2002).
  CAS PubMed Google Scholar
• Streit, M. et al. Thrombospondin-2: a potent endogenous inhibitor of tumour growth and angiogenesis. Proc. Natl Acad. Sci. USA 96, 14888–14893 (1999).
  CAS PubMed PubMed Central Google Scholar
• Viloria-Petit, A. et al. Acquired resistance to the antitumour effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumour angiogenesis. Cancer Res. 61, 5090–5101 (2001).
  CAS PubMed Google Scholar
• Koch, A. E. et al. Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint. Arthritis Rheum. 44, 31–40 (2001).
  CAS PubMed Google Scholar
• Ciardiello, F. et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 7, 1459–1465 (2001).
  CAS PubMed Google Scholar
• Kaban, L. B. et al. Anti-angiogenic therapy of a recurrent giant cell tumour of the mandible with interferon alfa-2α. Pediatrics 103, 1145–1149 (1999).
  CAS PubMed Google Scholar
• Marler, J. J. et al. Successful anti-angiogenic therapy of giant cell angioblastoma with interferon α 2β: report of two cases. Pediatrics 109, 1–5 (2002).
  Google Scholar
• Singh, R. K. et al. Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl Acad. Sci. USA 92, 4562–4566 (1995).
  CAS PubMed PubMed Central Google Scholar
• Brouty Boye, D. & Zetter, B. R. Inhibition of cell motility by interferon. Science 208, 516–518 (1980).
  CAS PubMed Google Scholar
• Kisker, O. et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumour model. Cancer Res. 61, 7669–7674 (2001).
  CAS PubMed Google Scholar
• Ingber, D. et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348, 555–557 (1990).
  CAS PubMed Google Scholar
• Griffith, E. D. et al. Methionine aminopeptidase (type 2) is the common target for aniogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol. 4, 461–471 (1997).
  CAS PubMed Google Scholar
• Sin, N. et al. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl Acad. Sci. USA 94, 6099–6103 (1997).
  CAS PubMed PubMed Central Google Scholar
• Kudelka, A. P., Verschraegen, C. F. & Loyer, E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor, TNP-470. N. Engl. J. Med. 338, 991–992 (1998).
  CAS PubMed Google Scholar
• Bhargava, P. et al. A study of TNP-470 in patients with advanced cancer. Proc. Am. Assoc. Cancer Res. 38, 221, abstract 1489 (1997).
  Google Scholar
• Stadler, W. M. et al. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol. 17, 2541–2545 (1999).
  CAS PubMed Google Scholar
• Zukiwski, A. et al. Phase I trial of the angiogenesis inhibitor TNP-470 (AGM-1470) in patients (Pts) with androgen independent prostate cancer (AI PCa). Proc. Am. Assoc. Soc. Clin. Oncol. 13, A795 (1994).
  Google Scholar
• Dezube, B. J. et al. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J. Clin. Oncol. 16, 1444 (1998).
  CAS PubMed Google Scholar
• Jain, R. K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl Cancer Inst. 81, 570–576 (1989).The demonstration that increased tissue pressure in tumours results from increased permeability of tumour vessels and interferes with delivery of therapeutic agents to tumours.
  CAS PubMed Google Scholar
• Shweiki, D., Itin, A., Soffer, D. & Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia initiated angiogenesis. Nature 359, 843–845 (1992).
  CAS PubMed Google Scholar
• Birner, P. et al. Overexpression of hypoxia-inducible factor-1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60, 4693–4696 (2000).
  CAS PubMed Google Scholar
• Aebersold, D. M. et al. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61, 2911–2916 (2001).
  CAS PubMed Google Scholar
• Shima, D. T., Deutsch, U. & D'Amore, P. A. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett. 370, 203–208 (1995).
  CAS PubMed Google Scholar
• Holmgren, L., O'Reilly, M. S. & Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1, 149–153 (1995).
  CAS PubMed Google Scholar
• Browder, T. et al. Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878–1886 (2000).
  CAS PubMed Google Scholar
• Teicher, B. A. et al. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat. Oncol. Invest. 2, 269–276 (1995).
  Google Scholar
• Mauceri, H. J. et al. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 394, 287–291 (1998).
  CAS PubMed Google Scholar
• Teicher, B. A. et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer 57, 920–925 (1994).
  CAS PubMed Google Scholar
• Gorski, D. H. et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59, 3374–3378 (1999).
  CAS PubMed Google Scholar
• Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Med. 7, 987–989 (2001).
  CAS PubMed Google Scholar
• Herbst, R. S. et al. Phase I clinical trial of recombinant human endostatin (rHE) in patients (pts) with solid tumors: Pharmacokinetic (pk), safety and efficacy analysis using surrogate endpoints of tissue and radiologic response. Proc. Am. Soc. Clin. Oncol. 20, 3a, abstract 9 (2001).
  Google Scholar
• Libutti, S. K., Choyke, P., Carrasquillo, J. A., Bacharach, S., & Neumann, R. D. Monitoring responses to antiangiogenic agents using noninvasive imaging tests. Cancer J. Sci. Am. 5, 252–256 (1999).
  CAS PubMed Google Scholar
• Kurdziel, K. et al. Using PET 18F-FDG, 11CO and 15O–water for monitoring prostate cancer during a phase II anti-angiogenic drug trial with thalidomide. Clin. Positron Imaging 3, 144 (2000).
  CAS PubMed Google Scholar
• Choyke, P. L., Knopp, M. V. & Libutti, S, K., Special techniques for imaging blood flow to tumors. Cancer J. 8, 109–118 (2002).
  PubMed Google Scholar
• Rak, J. W., St Croix, B. D. & Kerbel, R. S. Consequences of angiogenesis for tumour progression, metastasis and cancer therapy. Anti-Cancer Drugs 6, 3–18 (1995).
  CAS PubMed Google Scholar
• Dixelius, J. et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 95, 3403–3411(2000).
  CAS PubMed Google Scholar
• Graeber, T. G. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88–91 (1996).
  CAS PubMed Google Scholar
• Blagosklonny, M. V. Hypoxia-inducible factor: Achilles' heel of anti-angiogenic cancer therapy. Int. J. Oncol. 19, 257–262 (2001).
  CAS PubMed Google Scholar
• Yu, J. L., Rak, J., Carmeliet, P. & Coomber, B. L. Heterogenous vascular dependence of tumour populations. Am. J. Pathol. 158, 1325–1334 (2001).
  CAS PubMed PubMed Central Google Scholar
• Soengas, M. S. et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207–211 (2001).
  CAS PubMed Google Scholar
• Furuwatari, C. et al. A comprehensive system to explore p53 mutations. Am. J. Clin. Pathol. 110, 368–373 (1998).
  CAS PubMed Google Scholar
• Monestiroli, S. et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 61, 4341–4344 (2001).
  CAS PubMed Google Scholar
• Beecken, W.-D. C. et al. Effect of anti-angiogenic therapy on slowly growing, poorly vascularized tumours in mice. J. Natl Cancer Inst. 93, 382–387 (2001).
  CAS PubMed Google Scholar
• Gorelik, E., Segal, S. & Feldman, M. Growth of a local tumour exerts a specific inhibitory effect on progression of lung metastases. Int. J. Cancer 21, 617–625 (1978).
  CAS PubMed Google Scholar
• Perletti, G. et al. Antitumour activity of endostatin against carcinogen-induced rat primary mammary tumours. Cancer Res. 60, 1793–1796 (2000).
  CAS PubMed Google Scholar
• Sugarbaker, E. V., Thornwaite, J. & Ketcham, A. S. in Progress in Cancer Research and Therapy (eds Day, S. B., Myers, W. P., Stansly, P., Garatini, S. & Lewis, M. G.) 227–240 (Raven Press, New York, 1997).
  Google Scholar
• Gorelik, E. Concomitant tumour immunity and the rsistance to a second tumour challenge. Adv. Cancer Res. 39, 71–120 (1983).
  CAS PubMed Google Scholar
• O'Reilly, M. S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315–328 (1994).
  CAS PubMed Google Scholar
• Camphausen, K. et al. Radiation therapy to a primary tumour accelerates metastatic growth in mice. Cancer Res. 61, 2207–2211 (2001).
  CAS PubMed Google Scholar
• Lay, A. J. et al. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature 408, 869–873 (2000).
  CAS PubMed Google Scholar
• O'Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell 88, 277–285 (1997).
  Article CAS PubMed Google Scholar
• Wen, W., Moses, M. A., Wiederschain, D., Arbiser, J. L. & Folkman, J. The generation of endostatin is mediated by elastase. Cancer Res. 59, 6052–6056 (1999).
  CAS PubMed Google Scholar
• Felbor, U. et al. Secreted cathepsin L generates endostatin from Collagen XVIII. EMBO J. 19, 1187–1194 (2000).
  CAS PubMed PubMed Central Google Scholar
• O'Reilly, M. S., Pirie–Shepherd, S., Lane, W. S. & Folkman, J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285, 1926–1928 (1999).
  CAS PubMed Google Scholar
• Kisker, O. et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res. 61, 7298–7304 (2001).
  CAS PubMed Google Scholar
• Folkman J. in Accomplishments in Cancer Research (eds Wells, S. A. Jr & Sharpe, P. A.) 32–44 (Lippincott Williams & Wilkins, Pennsylvania, 1998).
  Google Scholar
• Brem, H. & Folkman, J. Analysis of experimental anti-angiogenic therapy. J. Pediatr. Surg. 28, 445–451 (1993).
  CAS PubMed Google Scholar
• Hori, K., Li, H. C., Saito, S. & Sato, Y. Increased growth and incidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470. Br. J. Cancer 75, 1730–1734 (1997).
  CAS PubMed PubMed Central Google Scholar
• Folkman, J., Mulliken, J. B. & Ezekowitz, R. A. B. in The Clinical Applications of the Interferons (eds Stuart–Harris, R. & Penny, R.) 255–265 (Chapman & Hall Medical, London, 1997).
  Google Scholar
• Kerbel, R. S. et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for combination therapy. Cancer Metastasis Rev. 20, 79–86 (2001).
  CAS PubMed Google Scholar
• Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumour regression without overt toxicity. J. Clin. Invest. 105, R15–R24 (2000).
  CAS PubMed PubMed Central Google Scholar
• Yang, J. C., Haworth, L., Steinberg, S. M., Rosenberg, S. A. & Novotny, W. A randomized double-blind placebo-controlled trial of bevacizumab anti-VEGF antibody demonstrating a prolongation time to progression in patients with metastatic renal cancer. Proc. Am. Soc. Clin. Oncol. 21, 15 (2002).
  Google Scholar
• Belotti, D. et al. The microtubule-affecting drug paclitaxel has anti-angiogenic activity. Clin. Cancer Res. 2, 1843–1849 (1996).
  CAS PubMed Google Scholar
• Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J. Clin. Oncol. 16, 301–308 (1998).
• Gabra, H., Cameron, D. A., Lee, L. E., Mackay, J. & Leonard, R. C. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. Br. J. Cancer 74, 2008–2012 (1996).
  CAS PubMed PubMed Central Google Scholar
• Hansen, R. M. et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J. Natl Cancer Inst. 88, 668–674 (1996).
  CAS PubMed Google Scholar
• Abu-Rustum, N. R. et al. Salvage weekly paclitaxel in recurrent ovarian cancer. Semin. Oncol. 24 (Suppl. 15), 62–67 (1997).
  Google Scholar
• Loffler, T. M., Freund, W., Lipke, J. & Hausamen, T. U. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumours: results of a phase I/II trial. Semin. Oncol. 23 (Suppl. 16), 32–34 (1996).
  CAS PubMed Google Scholar
• Kakolyris, S. et al. Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am. J. Clin. Oncol. 21, 505–508 (1998).
  CAS PubMed Google Scholar
• Chamberlain, M. C. Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Arch. Neurol. 54, 554–558 (1997).
  CAS PubMed Google Scholar
• Neskovic–Konstantinovic, Z. B., Bosnjak, S. M., Radulovic, S. S. & Mitrovic, L. B. Daily oral etoposide in metastatic breast cancer. Anticancer Drugs 7, 543–547 (1996).
  PubMed Google Scholar
• Hanahan, D., Bergers, G. & Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumour angiogenesis in mice. J. Clin. Invest. 105, 1045–1047 (2000).
  CAS PubMed PubMed Central Google Scholar
• Takahashi, N., Haba, A., Matsuno, F. & Seon, B. K. Anti-angiogenic therapy of established tumours in skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res. 61, 7846–7854 (2001).
  CAS PubMed Google Scholar
• Soffer, S. Z. et al. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumour. J. Pediatr. Surg. 36, 1781–1784 (2001).
  CAS PubMed Google Scholar
• Gimbrone, M. A. Jr, Cotran, R. S., Leapman, S. B. & Folkman, J. Tumor growth and neovascularization: an experimental model using rabbit cornea. J. Natl Cancer Inst. 52, 413–427 (1974).
  PubMed Google Scholar
• D'Amato, R. J., Loughnan, M. S., Flynn, E. & Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91, 4082–4085 (1994).
  CAS PubMed PubMed Central Google Scholar
• Verheul, H. M. W., Panigray, D., Yuan, J. & D'Amato, R. J. Combination oral anti-angiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br. J. Cancer 79, 114–118 (1999).
  CAS PubMed PubMed Central Google Scholar
• Singhal, S. et al. Antitumour activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565–1571 (1999).
  CAS PubMed Google Scholar
• Rajkumar, S. V. et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin. Proc. 75, 897–901 (2000).
  CAS PubMed Google Scholar
• Zomas, A., Anagnostopoulos, N. & Dimopoulos, M. A. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. Bone Marrow Transplant. 25, 1319–1320 (2000).
  CAS PubMed Google Scholar
• Weber, D. M. et al. Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (MM). Blood 96, 168a, abstract 724 (2000).
  Google Scholar
• Pini, M. et al. Low-dose of thalidomide in the treatment of refractory myeloma. Haematologica 85, 1111–1112 (2000).
  CAS PubMed Google Scholar
• Palmblad, J. Angiogenesis in hematologic malignancies with focus on multiple myeloma. Haema 4, 89–98 (2001).
  Google Scholar
• Folkman, J., Browder, T. & Palmblad, J. Angiogenesis research: guidelines for translation to clinical application. Thromb. Haemost. 86, 23–33 (2001).
  CAS PubMed Google Scholar
• Settles, B. et al. Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-α agent thalidomide. Cell Mol Biol (Noisy-le-grand) 47, 1105–1114 (2001).
  CAS Google Scholar
• Bauditz, J., Wedel, S. & Lochs, H. Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50, 196–200 (2002).
  CAS PubMed PubMed Central Google Scholar
• D'Amato, R. J., Lentzsch, S., Anderson, K. C. & Rogers, M. S. Mechanism of action of thalidomide and 3-amino-thalidomide in multiple myeloma. Semin. Oncol. 28, 597–601 (2001).
  CAS PubMed Google Scholar
• Folkman, J. Angiogenesis-dependent disease. Semin. Oncol. 28, 536–542 (2001).
  CAS PubMed Google Scholar
• Bertolini, F. et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann. Oncol. 12, 987–990 (2001).
  CAS PubMed Google Scholar
• Raje, N. & Anderson, K. Thalidomide: a revival story. N. Engl. J. Med. 341, 1606–1609 (1999).
  CAS PubMed Google Scholar
• Weidner, N., Semple, J. P., Welch, W. R. & Folkman, J. Tumour angiogenesis and metastasis: correlation in invasive breast carcinoma. N. Engl. J. Med. 324, 1–8 (1991).
  CAS PubMed Google Scholar
• Rajkumar, S. V., Fonseca, R., Witzig, T. E., Gertz, M. A. & Greipp, P. R. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 13, 469–472 (1999).
  CAS PubMed Google Scholar
• Folkman, J. in Cancer Medicine 5th edn (eds Holland, J. F. et al.) 132–152 (B. C. Decker, Inc., Ontario, Canada, 2000).
  Google Scholar
• Hlatky, L., Hahnfeldt, P. & Folkman, J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl Cancer Inst. 94, 883–893 (2002).
  PubMed Google Scholar
• Pinedo, H. M., Verheul, H. M. W., D'Amato, R. J. & Folkman, J. Involvement of platelets in tumour angiogenesis? Lancet 352, 1775–1777 (1998).
  CAS PubMed Google Scholar
• Sidky, Y. A. & Borden, E. C. Inhibition of angiogenesis by interferons: effects on tumour- and lymphocyte-induced vascular responses. Cancer Res. 47, 5155–5161 (1987).
  CAS PubMed Google Scholar
• Dvorak, H. F. & Gresser, I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumours in mice. J. Natl Cancer Inst. 81, 497–502 (1989).
  CAS PubMed Google Scholar
• Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P. N. & Fidler, I. J. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 5, 2726–2734 (1999).
  CAS PubMed Google Scholar
• Takahashi, K. et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J. Clin. Invest. 93, 2357–2364 (1994).
  CAS PubMed PubMed Central Google Scholar
• Bielenberg, D. R. et al. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-β. Int. J. Oncol. 14, 401–408 (1999).
  CAS PubMed Google Scholar
• White, C. W., Sondheimer, H. M., Crouch, E. C., Wilson, H. & Fan, L. L. Treatment of pulmonary hemangiomatosis with recombinant interferon α-2α. N. Engl. J. Med. 320, 1197–1200 (1989).
  CAS PubMed Google Scholar
• Folkman, J. Successful treatment of an angiogenic disease. N. Engl. J. Med. 320, 1211–1212 (1989).
  CAS PubMed Google Scholar
• Ezekowitz, R. A., Mulliken, J. B. & Folkman, J. Interferon α2A therapy for 'life-threatening' hemangiomas in infancy. N. Engl. J. Med. 326, 1456–1463 (1992).
  CAS PubMed Google Scholar
• Mulliken, J. B. et al. Pharmacologic therapy for endangering hemangiomas. Curr. Opin. Dermatol. 2, 109–113 (1995).
  Google Scholar
• Kaban, L. B. et al. Anti-angiogenic therapy with interferon-α for giant cell lesions of the jaws. J. Oral Maxillofac. Surg. 60, 1103–1111 (2002).
  PubMed Google Scholar
• Palmieri, G., Montella, L., Martignetti, A. & Bianco, A. R. Interferon α-2b at low doses as long-term anti-angiogenic treatment of a metastatic intracranial hemangioendothelioma: a case report. Oncol. Rep. 7, 145–149 (2000).
  CAS PubMed Google Scholar
• Deb, G. et al. Hemangioendotheliomas: successful therapy with interferon-α. A study in association with the Italian Pediatric Haematology/Oncology Society (AIEOP). Med. Pediatr. Oncol. 38, 118–119 (2002).
  PubMed Google Scholar
• Hansma, A. H. G. et al. A phase I study of rhEndostatin: continuous intravenous (i. v.) followed by subcutaneous (s. c.) administration. Proc. Am. Soc. Clin. Oncol. 21, abstract 436 (2002).
• Folkman, J., Hahnfeldt, P. & Hlatky, L. in The Development of Human Gene Therapy (ed. Friedmann, T.) 527–543 (Cold Spring Harbor Laboratory Press, New York, 1998).
  Google Scholar
• Blezinger, P. et al. Systemic inhibition of tumour growth and tumour metastases by intramuscluar administration of the endostatin gene. Nature Biotechnol. 17, 343–348 (1999).
  CAS Google Scholar
• Ding, I. et al. Intratumoural administration of endostatin plasmid inhibits vascular growth and perfusion in Mca murine mammary carcinoma. Cancer Res. 61, 526–531 (2001).
  CAS PubMed Google Scholar
• Read, T. A. et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nature Biotechnol. 19, 29–34 (2001).
  CAS Google Scholar
• Joki, T. et al. Continuous release of endostatin from microencapsulated engineered cells for tumour therapy. Nature Biotechnol. 19, 35–39 (2001).
  CAS Google Scholar
• Kuo, C. J. et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl Acad. Sci. USA 98, 4605–4610 (2001).
  CAS PubMed PubMed Central Google Scholar
• Feldman, A. L. et al. Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J. Natl Cancer Inst. 93, 1014–1020 (2001).
  CAS PubMed Google Scholar
• Scappaticci, F. A. et al. Combination angiostatin and endostatin gene transfer induces synergistic activity in vitro and antitumour efficacy in leukemia and solid tumours in mice. Mol. Ther. 3, 186–196 (2001).
  CAS PubMed Google Scholar
• Shi, W., Teschendorf, C., Muzyczka, N. & Siemann, D. W. Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther. 9, 513–521 (2002).
  CAS PubMed Google Scholar
• Calvo, A., Feldman, A. L., Libutti, S. K. & Green, J. E. Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3 (1)/SV40 T-antigen transgenic mice. Cancer Res. 62, 3934–3938 (2002).
  CAS PubMed Google Scholar
• Indraccolo, S. et al. Differential effects of angiostatin, endostatin and interferon-α1 gene transfer on in vivo growth of human breast cancer cells. Gene Ther. 9, 867–878 (2002).
  CAS PubMed Google Scholar
• Pawliuk, R. et al. Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol. Ther. 5, 345–351 (2002).
  CAS PubMed Google Scholar
• Eisterer, W. et al. Unfulfilled promise of endostatin in a gene therapy xenotransplant model of human acute lymphocytic leukemia. Mol. Ther. 5, 352–359 (2002).
  CAS PubMed Google Scholar
• Folkman, J. Regulation of angiogenesis. Blood 82 (Suppl. 1), 60 (1993).
• Brunner, G., Nguyen, H., Gabrilove, J., Rifkin, D. B. & Wilson, E. L. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood 81, 631–638 (1993).
  CAS PubMed Google Scholar
• Nguyen, M. et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl Cancer Inst. 86, 356–361 (1994).
  CAS PubMed Google Scholar
• Vacca, A. et al. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol. 87, 503–508 (1994).
  CAS PubMed Google Scholar
• Ribatti, D. et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br. J. Cancer 79, 451–455 (1999).
  CAS PubMed PubMed Central Google Scholar
• Vacca, A. et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion, parallel progression of human multiple myeloma. Blood 93, 3064–3073 (1999).
  CAS PubMed Google Scholar
• Vacca, A., Ribatti, D., Roncali, L. & Dammacco, F. Angiogenesis B cell lymphoproliferative diseases. Biological and clinical studies. Leuk. Lymphoma 20, 27–38 (1995).
  CAS PubMed Google Scholar
• Rak, J. et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55, 4575–4580 (1995).
  CAS PubMed Google Scholar
• Brem, S., Cotran, R. & Folkman, J. Tumour angiogenesis: a quantitative method for histologic grading. J. Natl Cancer Inst. 48, 347–356 (1972).
  CAS PubMed Google Scholar
• Mlynek, M. L., van Beunigen, D., Leder, L. D. & Streffer, C. Measurement of the grade of vascularisation in histological tumour tissue sections. Br. J. Cancer 52, 945–948 (1985).
  CAS PubMed PubMed Central Google Scholar
• Srivastava, A., Laidler, P., Davies, R. P., Horgan, K. & Hughes, L. E. The prognostic significance of tumour vascularity in intermediate-thickness (0.76–4.0 mm thick) skin melanoma. A quantitative histologic study. Am. J. Pathol. 133, 419–423 (1988).
  CAS PubMed PubMed Central Google Scholar
• Achilles, E.-G. et al. Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for 'no take' of human tumours in mice. J. Natl Cancer Inst. 93, 1075–1081 (2001).
  CAS PubMed Google Scholar
• Gasparini, G. & Harris, A. L. in Antiangiogenic Agents in Cancer Therapy (ed. Teicher, B. A.) 317–339 (Humana Press, New Jersey, 1999).
  Google Scholar
• Moser, T. L. et al. Angiogstatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl Acad. Sci. USA 96, 2811–2816 (1999).
  CAS PubMed PubMed Central Google Scholar
• Troyanovsky, B., Levchenko, T., Mansson, G., Matvjenko, O. & Holmgren, L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J. Cell Biol. 152, 1247–1254 (2001).
  CAS PubMed PubMed Central Google Scholar
• Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D 3, 28–30 (2002).
• Colorado, P. C. et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 60, 2520–2526 (2000).
  CAS PubMed Google Scholar
• Kamphaus, G. D. et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 275, 1209–1215 (2000).
  CAS PubMed Google Scholar
• Kanthou, C. & Tozer, G. M. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskleton and early membrane blebbing in human endothelial cells. Blood 99, 2060–2069 (2002).
  CAS PubMed Google Scholar
• Reimer, C. L. et al. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, and inhibitor of angiogenesis. Cancer Res. 62, 789–795 (2002).
  CAS PubMed Google Scholar
• Maeshima, Y. et al. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J. Biol. Chem. 276, 15240–15248 (2001).
  CAS PubMed Google Scholar
• Maeshima, Y. et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295, 140–143 (2002).
  CAS PubMed Google Scholar
• Gutheil, J. C. et al. Targeted antiangiogenic therapy for cancer using vitaxin: a humanized monoclonal antibody to the integrin αvβ3. Clin. Cancer Res. 6, 3056–3061 (2000).
  CAS PubMed Google Scholar
• Tille, J. C. et al. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J. Pharmacol. Exp. Ther. 299, 1073–1085 (2001).
  CAS PubMed Google Scholar
• Mendel, D. B. et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin. Cancer Res. 6, 4848–4858 (2000).
  CAS PubMed Google Scholar
• Hoekman, K. SU6668, a multitargeted angiogenesis inhibitor. Cancer J. 7, S134–S138 (2001).
  PubMed Google Scholar
• Rak, J. et al. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 14, 263–277 (1995).
  CAS PubMed Google Scholar
• Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B. & Marme, D. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem. 270, 25915–25919 (1995).
  CAS PubMed Google Scholar
• Rak, J. et al. Oncogenes and tumor angiogenesis: different modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res. 60, 490–498 (2000).
  CAS PubMed Google Scholar
• Zabrenetsky, V., Harris, C. C., Steeg, P. S. & Roberts, D. D. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer 59, 191–195 (1994).
  Google Scholar
• Mukhopadhyay, D., Tsiokas, L. & Sukhatme, V. P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55, 6161–6165 (1995).
  CAS PubMed Google Scholar
• Mukhopadhyay, D. et al. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375, 577–581 (1995).
  CAS PubMed Google Scholar
• Slack, J. L. & Bornstein, P. Transformation by v-src causes transient induction followed by repression of mouse thrombospondin-1. Cell Growth Differ. 5, 1373–1380 (1994).
  CAS PubMed Google Scholar
• Bein, K., Ware, J. A. & Simons, M. Myb-dependent regulation of thrombospondin 2 expression. Role of mRNA stability. J. Biol. Chem. 273, 21423–21429 (1998).
  CAS PubMed Google Scholar
• Meitar, D., Crawford, S. E., Rademaker, A. W. & Cohn, S. L. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J. Clin. Oncol. 14, 405–414 (1996).
  CAS PubMed Google Scholar
• Fotsis, T. et al. Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells. Eur. J. Biochem. 263, 757–764 (1999).
  CAS PubMed Google Scholar
• Pelengaris, S., Littlewood, T., Khan, M, Elia, G. & Evan, G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell 3, 565–577 (1999).
  CAS PubMed Google Scholar
• Perrotte, P. et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5, 257–265 (1999).
  CAS PubMed Google Scholar
• Sheibani, N. & Frazier, W. A. Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells. Cancer Lett. 107, 45–52 (1996).
  CAS PubMed Google Scholar
• Saez, E. et al. c-Fos is required for malignant progression for skin tumors. Cell 82, 721–732 (1995).
  CAS PubMed Google Scholar
• McGregor, L. M. et al. Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc. Natl Acad. Sci. USA 96, 4540–4545 (1999).
  CAS PubMed PubMed Central Google Scholar
• Le Buanec, H. et al. HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes. Biomed. Pharmacother. 53, 424–531 (1999).
  CAS PubMed Google Scholar
• Lopez-Ocejo, O. et al. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 19, 4611–4620 (2000).
  CAS PubMed Google Scholar
• Jiang, B. H., Zheng, J. Z., Aoki, M. & Vogt, P. K. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl Acad. Sci. USA 97, 1749–1753 (2000).
  CAS PubMed PubMed Central Google Scholar
• Auvinen, M. et al. Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice. Cancer Res. 57, 3016–3025 (1997).
  CAS PubMed Google Scholar
• Heaney, A. P., Horwitz, G. A., Wang, Z., Singson, R. & Melmed, S. Early involvement of estrogen-inducing pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nature Med. 5, 1317–1321 (1999).
  CAS PubMed Google Scholar
• Fu, X., Roberts, W. G., Nobile, V., Shapiro, R. & Kamps, M. P. mAngiogenin-3, a target of oncoprotein E2a-Pbx1, encodes a new angiogenic member of the angiogenin family. Growth Factors 17, 125–137 (1999).
  CAS PubMed Google Scholar